
## Robert M Dean

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8406578/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. Journal of Clinical Investigation, 2015, 125, 1043-1055.	3.9	79
2	Impact of comorbidities on outcomes of elderly patients with diffuse large B ell lymphoma. American Journal of Hematology, 2017, 92, 989-996.	2.0	33
3	Intravenous Compared to Oral Busulfan with Cyclophophamide for Allogeneic Hematopoietic Progenitor Cell Transplant Conditioning for AML and MDS Blood, 2010, 116, 3475-3475.	0.6	32
4	Elevated Pretransplant Serum Ferritin in Autologous Stem Cell Transplant Blood, 2007, 110, 606-606.	0.6	31
5	Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1029-1034.	2.0	19
6	Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 262-271.	2.0	17
7	Effect of bone marrow CD34+cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2019, 54, 775-781.	1.3	14
8	Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 857-862.	0.2	13
9	Progression with clinical features is associated with worse subsequent survival in multiple myeloma. American Journal of Hematology, 2019, 94, 439-445.	2.0	12
10	Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Leukemia and Lymphoma, 2018, 59, 1195-1201.	0.6	11
11	Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times–Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1588-1595.	2.0	9
12	Association of Socioeconomic Status with Outcomes ofÂAutologous Hematopoietic Cell Transplantation for MultipleÂMyeloma. Biology of Blood and Marrow Transplantation, 2016, 22, 1141-1144.	2.0	9
13	BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2019, 25, 1107-1115.	2.0	9
14	DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. Seminars in Hematology, 2021, 58, 45-55.	1.8	8
15	Early stage, bulky Hodgkin lymphoma patients have a favorable outcome when treated with or without consolidative radiotherapy: potential role of <scp>PET</scp> scan in treatment planning. British Journal of Haematology, 2017, 179, 674-676.	1.2	7
16	Influence of major histocompatibility complex class I chain-related gene A polymorphisms on cytomegalovirus disease after allogeneic hematopoietic cell transplantation. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 32-39.	0.6	7
17	A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies. Seminars in Hematology, 2021, 58, 35-44.	1.8	7
18	Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis. Leukemia and Lymphoma, 2021, 62, 1344-1352.	0.6	7

Robert M Dean

#	Article	IF	CITATIONS
19	Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR. Blood, 2018, 132, 697-697.	0.6	7
20	Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, aÂSingle-Institution Experience. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e95-e102.	0.2	6
21	BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas. Bone Marrow Transplantation, 2019, 54, 1553-1561.	1.3	6
22	Novel Targeted Therapies for Chronic Lymphocytic Leukemia in Elderly Patients: A Systematic Review. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e414-e426.	0.2	6
23	Neutropenic Fever During Stem Cell Mobilization Is Associated with Decreased CD34+ Cell Collection and Poor Survival Following Autologous Stem Cell Transplantation,. Blood, 2011, 118, 4053-4053.	0.6	6
24	The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma. Leukemia and Lymphoma, 2022, 63, 335-343.	0.6	5
25	Co-expression of MYC and BCL2 predicts poorer outcomes for relapsed/refractory diffuse large B-cell lymphoma with R-ICE and intent to transplant. Therapeutic Advances in Hematology, 2018, 9, 81-87.	1.1	4
26	A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma. Leukemia and Lymphoma, 2018, 59, 690-694.	0.6	4
27	Long-term survival after high-dose chemotherapy with autologous hematopoietic cell transplantation in metastatic breast cancer. Hematology/ Oncology and Stem Cell Therapy, 2015, 8, 115-124.	0.6	3
28	Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era. Blood, 2019, 134, 4567-4567.	0.6	3
29	Elevated Ferritin Is Associated with Poorer Survival Following Nonablative Allogeneic Transplantation Blood, 2007, 110, 1986-1986.	0.6	3
30	Analysis of Readmission After Autologous HCT: Predictive Factors and Clinical Consequences. Blood, 2010, 116, 932-932.	0.6	3
31	Non-Cytotoxic Differentiation Therapy Based On Mechanism of Disease Produces Complete Remission in Myelodysplastic Syndromes (MDS) with High Risk Cytogenetics. Blood, 2012, 120, 1696-1696.	0.6	3
32	Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma. Blood, 2018, 132, 1899-1899.	0.6	3
33	Management of Asymptomatic Mucosa-Associated Lymphoid Tissue Lymphoma of the Colon Found Incidentally on Colonoscopy. Clinical Gastroenterology and Hepatology, 2017, 15, 1130-1132.	2.4	2
34	Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel. Blood, 2020, 136, 38-39.	0.6	2
35	Results of a Phase I Trial of Lenalidomide, Rituximab (R2) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma. Blood, 2020, 136, 1-2.	0.6	1
36	Prognostic Impact of Elevated Pretransplant Serum Ferritin in Allogeneic Hematopoietic Stem Cell Transplantation Blood, 2007, 110, 1109-1109.	0.6	1

Robert M Dean

#	Article	IF	CITATIONS
37	Long Term Follow Up with Etoposide Priming in Patients with Lymphoma Blood, 2007, 110, 1895-1895.	0.6	1
38	Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma. Blood, 2010, 116, 1967-1967.	0.6	1
39	Survival Outcomes in Patients with Waldenstr¶m Macroglobulinemia/ Lymphoplasmacytic Lymphoma According to MYD88 Mutation Status. Blood, 2019, 134, 5248-5248.	0.6	1
40	Evaluation of pre-transplant risk assessments in allogeneic hematopoietic cell transplant. Bone Marrow Transplantation, 2022, 57, 1031-1033.	1.3	1
41	Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoring. Journal of Oncology Pharmacy Practice, 0, , 107815522211044.	0.5	1
42	Disappointing Outcomes of Peripheral T Cell Lymphoma after Autologous Stem Cell Transplantation Blood, 2006, 108, 5428-5428.	0.6	0
43	Prior Therapy with Rituximab (R) in Patients with Follicular Lymphoma (FL) Does Not Affect Relapse-Free (RFS) or Overall Survival (OS) after High Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT) Blood, 2006, 108, 3069-3069.	0.6	0
44	Analysis of Factors Influencing Skin Toxicity after Autologous Hematopoeitic Stem Cell Transplant Blood, 2007, 110, 2882-2882.	0.6	0
45	High Rate of Survival in Transformed Lymphoma after Autologous Stem Cell Transplant (ASCT): Pathologic Analysis and Comparison with De Novo DLBCL Blood, 2008, 112, 1137-1137.	0.6	0
46	Days of Pheresis Needed for Harvesting CD34+ Cells for Autologous Hematopoietic Stem Cell Transplantation Is Associated with Speed of Neutrophil Recovery and the Development of Secondary AML/MDS Blood, 2009, 114, 2151-2151.	0.6	0
47	Risk Factors for 30-Day Hospital Readmission Following Myeloablative Allogeneic Stem Cell Transplantation Blood, 2010, 116, 1532-1532.	0.6	0
48	The Positive Effect of Inpatient Care-Partners During Allogeneic Bone Marrow Transplantation; A Prospective Trial. Blood, 2010, 116, 931-931.	0.6	0
49	Comparison of Single Versus Multiple Unit Umbilical Cord Blood Transplantation for Adult Hematologic Malignancy Patients. Blood, 2010, 116, 3545-3545.	0.6	0
50	Higher Non-Relapse Mortality with BuCyVP Compared to BuCy In Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2010, 116, 1340-1340.	0.6	0
51	Acute GVHD in AML and MDS Patients Receiving Matched Related Donor (MRD) Reduced-Intensity Conditioning Allogeneic Hematopoietic Progenitor Cell Transplant (RIC-AHPCT) Correlates with Major Histocompatibility Complex Class I-Related Molecule A (MICA) Gene Polymorphisms,. Blood, 2011, 118, 4072-4072.	0.6	0
52	Tandem Autologous Hematopoietic Progenitor Cell Transplantation (AHPCT) for High-Risk Hodgkin Lymphoma: Mature Results of a Prospective Trial. Blood, 2012, 120, 1990-1990.	0.6	0
53	Prognostic Factors for Late Mortality Among Day 100 Survivors after Allogeneic Hematopoietic Cell Transplantation (HCT). Blood, 2016, 128, 4666-4666.	0.6	0
54	Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia. Blood, 2018, 132, 2075-2075.	0.6	0

#	Article	IF	CITATIONS
55	A Phase I Trial of Venetoclax in Combination with BEAM Conditioning Chemotherapy (V-BEAM) with Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma. Blood, 2019, 134, 5705-5705.	0.6	0